Figure: Data show the neutralization ID50 ratio of each variant, compared with the D614G reference strain.
Figure: Fluorescence signals of GFP were normalized to the signal of the D614G reference strain after 1 h of co-incubation; values shown indicate means +- SEMs.
Figure: Neutralization activities of from animals immunized with D614G and other SARS-CoV-2 variants.
Figure: Normalized ID50 ratios compared to D614G reference strain are shown.
Figure: Normalized chemiluminescence signals (in RLUs) of target cells were calculated compared with the D614G reference strain.
Figure: Ratios of infectivity compared with the D614G reference strain were shown.
Figure: Reduced differences (compared with the D614G r
RT-LAMP assay for rapid detection of the R203M mutation in SARS-CoV-2 Delta variant.
Introduction: Delta variants have a number of characteristic mutations in their spike protein, including single-nucleotide polymorphisms (SNPs) resulting in T19R, R158G, L452R, T478 K, D614G, P681R, and D950N, which are usually chosen as the detection targets of the molecular diagnostics for Delta genotyping.
SARS-CoV-2 spike E156G/Delta157-158 mutations contribute to increased infectivity and immune escape.
Method: All other plasmids expressing spike protein mutants such as pcDNA 3.1 bs(-) T19R, pcDNA 3.1 bs(-) T95I, pcDNA 3.1 bs(-) E156G/Delta157-158, pcDNA 3.1 bs(-) L452R, pcDNA 3.1 bs(-) E484Q, pcDNA 3.1 bs(-) E156G/Delta157-158/L452R, pcDNA 3.1 bs(-) E156G/Delta157-158/E484Q, pcDNA 3.1 bs(-) E156G/Delta157-158/L452R/E484Q, and pcDNA 3.1 bs(-) ICS-05 were generated using site-directed mutagenesis by PCR using the pcDNA 3.1 bs(-) spike D614G plasmid as the template.
Identification of a novel SARS-CoV-2 variant with a truncated protein in ORF8 gene by next generation sequencing.
Abstract: This variant belongs to Pango lineage B.1.1291, which also contains the D614G mutation in the Spike (S) gene.
Table: D614G
Tracking SARS-CoV-2 variants by entire S-gene analysis using long-range RT-PCR and Sanger sequencing.
PMID: 35304093
2022
Clinica chimica acta; international journal of clinical chemistry
5Result: Samples that could not determine the lineage of SARS-CoV-2 because of the lack of specific mutation patterns except for S:D614G were classified as ""Undetermined."" To assess the dynamic of circulating SARS-CoV-2, we compared our data with the reported lineages in Chiba University Hospital."
Abstract: RESULTS: The S:D614G mutation was found in all samples.
Result: All of the sequenced samples had S:D614G mutation.
Figure: Undetermined includes various lineages of SARS-CoV-2 which could not be determined the lineages because of the lack of specific mutation patterns except for S:D614G.
In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate.
Abstract: Using a clinical strain of the Omicron variant, we analyzed the neutralizing power of eight currently used monoclonal antibodies compared to the ancestral B.1 BavPat1 D614G strain.
Method: Drosten through EVA GLOBAL (https://www.european-virus-archive.com/) and contains the D614G mutation.
Result: The ancestral D614G BavPat1 European strain (B.1 lineage) was used as a reference to calculate the fold change between the EC50s determined for each virus.
Figure: Dose response curves reporting the susceptibility of the SARS-CoV-2 BavPat1 D614G ancestral strain and Omicron variant to a panel of therapeutic monoclonal antibodies.
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
PMID: 35305699
2022
The Lancet. Infectious diseases
Abstract: However, S309, the parent of sotrovimab, retained most of its activity, with only an approximately two-fold reduction in potency against the omicron variant compared with ancestral D614G SARS-CoV-2 (IC50 0 1-0 2 mug/mL).
Method: Plasmids encoding the spikes from the B.1 (D614G), mu (B.1.621), and delta variants were obtained from the G2P-UK National Virology consortium.
Result: However, the parent antibody of sotrovimab, S309, maintained its activity, with only a two-fold reduction in potency against the omicron variant compared with ancestral B.1 (D614G) virus (table 2), which is likely to be attributable to the location of the epitope that sotrovimab binds to being outside of the highly mutated receptor binding motif.
Table: D614G
Emergence of Progressive Mutations in SARS-CoV-2 From a Hematologic Patient With Prolonged Viral Replication.
Result: Mutation D614G was found in the first virus analyzed in accordance with the lineage B.1.
Result: Supplementary Figure S5 showed the 7 amino acid changes in the Spike of virus detected in the last sample: S12F, T95I, L141F, E484Q, S494L, D614G, and I770V.
Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations?
Introduction: One such VOC, B.1.617.2, also known as the Delta variant and first identified in India in October 2020, is characterized by mutations T19R, G142D, Delta157-158, R158G, L452, T478K, D614G, P681R, and D950N in the spike protein.
Table: D614G
2'-O-Methyl modified guide RNA promotes the single nucleotide polymorphism (SNP) discrimination ability of CRISPR-Cas12a systems.
Conclusion: Secondly, HBV genotyping and SARS-CoV-2 D614G mutant biosensing platforms were established to validate the high specificity and versatility of the Cas12a system.
Result: 2'-OMe modifications of gRNA increased the specificity for the SARS-CoV-2 D614G mutant detection.
Result: Accordingly, we designed one unmodified gRNA complementary to the SARS-CoV-2 D614G mutant (ugRNA-D614G).
Result: For target DNA at 1 nM and 0.1 nM, the final DF values of mgRNA-D614G-3' (1.43 +- 0.08 and 1.8 +- 0.1 for 1 nM and 0.1 nM, respectively) were abo
Result: all unmodified and modified gRNAs-D614G possessed high specificity even in the complex sample, demonstrating the stability of the Cas12a based D614G mutant biosensing platform.
SARS_CoV_2 mutation literature information.
PMID: 
2022
Emerging microbes & infections
Browser Board
Co-occurred Entities
Filtrator
ViMRT